Posted by Michael Wonder on 20 Nov 2021
NICE recommends Inrebic for rare blood cancer
19 November 2021 - NICE have issued a final appraisal determination recommending the use of Inrebic (fedratinib) on the NHS for the treatment of myelofibrosis, a rare blood cancer affecting the bone marrow and disrupting the body’s production of blood cells.
Eligible adult patients with primary or secondary myelofibrosis will now be able to access fedratinib on the NHS.
